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ABSTRACT
Food-producing animals are the primary reservoir of zoonotic pathogens, and the detection of extended
spectrum b-lactamase (ESBL) producers among Escherichia coli and Salmonella strains has increased in
recent years. ESBLs are widely detected in various human medical institutions but they are not so
frequently reported in the bacterial population circulating in animals. This could indicate that these
enzymes are less prevalent in animals than in humans, but also that they have not been extensively
sought. The increasing occurrence of ESBL producers in animals is highlighted and discussed in this
review with respect to the circulation of these resistance traits also among human pathogens.
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INTRODUCTION
Food-producing animals are considered to be the
primary reservoir of non-typhoidal Salmonella,
Escherichia coli and Campylobacter causing enteric
infection in humans. In the developed world,
zoonotic pathogens spread to humans through
the food chain via improper handling and inad-
equate cooking of food. Zoonotic pathogens usu-
ally cause a self-limiting diarrhoeal disease,
which normally does not require medical treat-
ment. Extended-spectrum cephalosporins and
ﬂuorinated quinolones are the antibiotics of
choice in the treatment of invasive salmonellosis,
so in complicated infections, the presence of
cephalosporin resistance becomes important and
can lead to treatment failure. Resistance in Salmo-
nella has been associated with larger outbreaks
and more severe and protracted illnesses than
when infections are sustained by non-resistant
strains [1]. In the veterinary context, the presence
of cephalosporin resistance in E. coli and Salmo-
nella has caused high levels of mortality and
morbidity in calves, and fatal infections in pets
[2,3].
Animals may also be the reservoir of the
resistant faecal ﬂora. Knowledge concerning
colonisation of the human gut is still incomplete
but it is well-known that endogenous faecal ﬂora
of animal origin can spread via the food chain and
transiently colonise the human gut. Resistant gut
colonisers (principally, E. coli) may be subsequent
agents of urinary infection in vulnerable patients.
Resistant non-pathogenic E. coli isolates have
been implicated in the transmission of genetic
resistance determinants; it has been demonstrated
also that genetic resistance traits can be trans-
ferred in the gut or via milk and meat [4].
However, it is still unclear whether there is a
direct exchange of resistance determinants
between animal and human pathogens and to
what extent the use of antimicrobials in veterinary
medicine provides selective pressure contributing
to the spread of resistance in human isolates. This
is a highly contentious issue, actively discussed
among those involved in veterinary and human
medicine.
The ﬁgures for worldwide antimicrobial usage
in food production are unavailable. The Animal
Health Institute in the USA has estimated that
more than 8000 tons of antimicrobials are used in
food production, corresponding to 4–25 g anti-
biotics/ton of feed (http://www.ahi.org). In the
Corresponding author and reprint requests: A. Carattoli,
Department of Infectious, Parasitic and Immune-Mediated
Diseases, Istituto Superiore di Sanita`, Viale Regina Elena
299, 00161 Rome, Italy
E-mail: alecara@iss.it
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 117–123
UK, cephalosporin use in veterinary medicine
amounted to 3 tons active ingredients in 2003 [5].
In veterinary medicine, the extended-spectrum
cephalosporins are prescription-only medicines,
limited to the treatment of clinical illness. Cefa-
lonium, cefoperazone, cefquinome, ceftiofur and
cefuroxime are the most frequently used cepha-
losporins, and are approved exclusively for the
treatment of animal diseases such as metritis, foot
rot and mastitis in cattle, respiratory diseases in
ruminants, horses and swine, necrotic enteritis
and colisepticaemia in poultry, and septicaemia
caused by E. coli in calves [5]. Cefotaxime and
cephalexin are among the ﬁrst-line treatments for
cystitis and skin wounds in cats and dogs.
Current literature often reports resistance to
newer cephalosporins in bacterial populations
isolated from animals, but only a limited number
of studies have investigated the molecular basis
of such resistance, determining the genes
accounting for the observed phenotypes. The
acquisition of b-lactamase genes by both Salmo-
nella and E. coli appears to have been on the rise
over recent years, with an increased number of
reports describing bacteria carrying genes that
confer resistance to the newer cephalosporins [5].
Many reports describe the emergence and spread
of zoonotic pathogens producing plasmid-
encoded Ambler class C b-lactamases, particu-
larly CMY-2, originating from the AmpC enzyme
of Citrobacter freundii [5]. It has been suggested
that the increase in CMY-2 producers observed in
the last decade in the USA is due to the use of
ceftiofur, licensed since 1988 and now approved
in many other countries [6]. The occurrence of
CMY-2 producers has been noted in several
countries, and the diffusion of this b-lactamase
seems to be linked to efﬁcient horizontal trans-
mission of its encoding plasmids [5]. By contrast,
there are very few reports describing class A
extended - spectrum b-lactamases (ESBLs) in
food-producing and companion animals, while a
large variety of producers from human infections
are reported worldwide [7,8]. This does not
necessarily indicate that ESBL genes are less
prevalent in the bacterial populations of animals
than in those of humans, since they might not
have been extensively investigated and—as a
consequence—the prevalence of ESBL genes in
animals could be underestimated. Table 1 reports
the current knowledge of ESBL producers iden-
tiﬁed in animals and food of animal origin. Of
course, this list is limited to the published reports
where the molecular mechanism of cephalosporin
resistance has been identiﬁed. The epidemiology
of particularly signiﬁcant ESBL producers in
animals is discussed below in order to evaluate
the contribution of animals as potential reservoirs
of producers of these clinically relevant b-lacta-
mases.
ESBL PRODUCERS IN ANIMALS
Since 1989, ESBL genes have been detected in
non-typhoidal salmonellae isolated from humans
in a number of hospitals in South America, North
Africa and eastern Europe [7,8]. These infections
were often associated with nosocomial epidemics,
and there was no clear association with food
consumption or contact with animals. The ﬁrst
detection of an ESBL in an animal was reported in
Japan in 1988, from a laboratory dog infected by
an FEC-1-producing E. coli strain [9].
Broad-spectrum SHV-1-, TEM-1- and OXA-
type b-lactamases have been frequently described
in E. coli and Salmonella spp. from animals and
food of animal origin in Spain, Germany, the USA
and the UK. TEM-1 was the most common variant
among these isolates [5,7], but it is only in the last
few years that some ESBLs known to be relevant
to human medicine have been described in
isolates from animals (Table 1).
CTX-M-1
E. coli isolates producing the CTX-M-1 enzyme
were ﬁrst reported in a healthy dog in Portugal
[10], but a signiﬁcant emergence of CTX-M-1
producers was recently observed in Italy in a
collection of 298 E. coli isolates, recovered from
both healthy and diseased pets (204 dogs and 61
cats). In this collection, 7% of the isolates showed
resistance to cefotaxime, 76% of them being CTX-
M-1 producers and 23% being positive for the
blaSHV-12 gene [15]. These organisms were isolated
from ﬁve kennels in the period 2000–2003: four
strains were from animals of private owners, and
the strains were genetically unrelated, thus dem-
onstrating possible horizontal transmission. In
Italy, off-label use of expanded-spectrum cepha-
losporins registered for human was widespread
in pet therapy since the early 1990s. Interestingly,
an increase in CTX-M-positive isolates from
humans was also observed in Italy during the
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period. CTX-M-1 and CTX-M-15 were the most
prevalent CTX-M variants [33]. Speciﬁcally, CTX-
M-1 increased from 12.5% in 1999 to 38.2% in
2003. These observations strongly suggest the
wide diffusion of this gene variant among bacte-
ria circulating in humans and animals. CTX-M-1
has recently been identiﬁed also in food-produc-
ing animals in Denmark, Spain and France
[11–14,16], thus suggesting a potential risk of
diffusion through zoonotic pathogens in the near
future in Europe.
CTX-M-2
The presence of CTX-M-2 producers in food
animals has been observed in Japan since 1999.
Among 2747 isolates from cattle, pig and
poultry farms, collected during 1999–2002, 18
Table 1. E. coli and salmonella ESBL producers in animals and food of animal origin
b-Lactamase Organisma No strains Country Source Reference
FEC-1 Escherichia coli 1 Japan Dog [9]
CTX-M-1 E. coli 1 Portugal Dog [10]
E. coli 31 Spain Cattle, pigs, poultry [11,12]
E. coli 19 France Cattle, pigs, poultry [13,14]
E. coli 20 Italy Pets [15]
E. coli 2 Denmark Pig [16]
CTX-M-2 E. coli 13 Japan Cattle, broiler [17,18]
S. Virchow 1 The Netherlands Broiler [19]
S. Virchow 1 Ireland Poultry [20]
S. Virchow 6 Belgium Poultry [21]
CTX-M-3 E. coli 4 Hong Kong Pig [22]
CTX-M-9 S. Virchow 8 France Poultry [23]
S. Virchow 3 Denmark Quails [24]
S. Virchow 2 Spain Broiler [25]
S Enteriditis 1 Spain Lay hen [25]
E. coli 13 Spain Poultry [11,12]
CTX-M-13 E. coli 2 Hong Kong Cattle [22]
CTX-M-14 E. coli 41 Spain Rabbit, poultry, pig [11,12,26]
E. coli 2 Japan Broiler [18]
E. coli 114 UK Cattle [27,28]
CTX-M-15 E. coli 1 France Poultry [13]
CTX-M-24 E. coli 1 Hong Kong Pig [22]
CTX-M-32 S. Virchow 2 Greece Poultry [29]
E. coli 3 Spain Poultry, pig [11,12]
SHV-12 S 35:c:1,2 1 Senegal Poultry [30]
S Newport 1 USA Horse [31]
S Typhimurium 1 The Netherlands Poultry [19]
S Rissen 1 Spain Pig [25]
E. coli 1 Spain Dog [2]
E. coli 19 Spain Poultry [11,12,26]
E. coli 3 Italy Dog [15]
SHV-5 E. coli 5 Spain Poultry, pig [12]
TEM-52 S Agona 3 Belgium Poultry [35]
S Blockley 6 The Netherlands Poultry [19]
S Derby 1 Belgium Poultry [35]
S Infantis 1 Belgium Poultry [35]
S Paratyphi B 1 The Netherlands Poultry [19]
S. Paratyphi B 1 Belgium Poultry [35]
S. Virchow 1 The Netherlands Poultry [19]
S. Typhimurium 3 The Netherlands Poultry [19]
S. Typhimurium 3 Belgium Poultry [32]
E. coli 3 Portugal Dog [10]
E. coli 3 Spain Rabbit, poultry [11,12]
E. coli 1 Denmark Beef [32]
aS., Salmonella enterica.
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cefazolin-resistant E. coli strains were recovered,
four of which produced CTX-M-2 and two CTX-
M-14 (otherwise called CTX-M-18) [17]. A Japa-
nese study involving 396 cattle faecal samples and
270 surface swabs of cattle carcasses, collected
during 2000–2001, conﬁrmed the occurrence of
CTX-M-2 in E. coli from animals [18]. CTX-M-2
was also extensively reported from humans in
Japan. In a collection of 317 cephalosporin-
resistant blaCTX-M-positive Gram-negative isolates
(E. coli, Klebsiella pneumoniae), collected during
2000–2003 in 132 Japanese hospitals, 161 pro-
duced CTX-M-2, 99 CTX-M-9 and 57 CTX-M-1
[34]. CTX-M-2 producers were found in the stools
of <0.5 of healthy humans in Japan; this preva-
lence was not signiﬁcantly different from that in
faecal cattle samples (1.5%) [17]. Although there
was no direct evidence of transmission of CTX-M-
2-producing E. coli strains from cattle to humans,
the presence of these producers on the surface of
cattle carcasses and in faeces strongly suggests
that these bacteria may be transmitted to humans
through the food chain [17]. In Europe, CTX-M-2-
positive serotype Virchow (Salmonella enterica
(S.) Virchow) producers have emerged in poultry
in The Netherlands, Ireland and Belgium in recent
years [19–21], thus suggesting the need for better
control of zoonotic pathogens in the near future,
with accurate surveillance to monitor the poten-
tial diffusion of this ESBL through the animal
reservoir.
CTX-M-9 and CTX-M-14
CTX-M-14 was detected among animals in one
healthy chicken in Spain in 2000 [25]. In a later
Spanish study performed in 2003, a 3% preva-
lence of ESBL producers was seen among E. coli
isolates with reduced susceptibility to cefotaxime.
Among the 619 E. coli isolates of this collection,
eight carried the CTX-M-14 variant and two the
CTX-M-9 variant [11]. Two CTX-M-9-producing
S. Virchow strains were more recently isolated
from poultry [25]. It is interesting to note that,
since the late 1990s, the closely related CTX-M-9
and CTX-M-14 variants have also prevailed
among human isolates. In studies performed in
Spain in that period, S. Virchow and E. coli with
CTX-M-9 were highly prevalent [36]. In the 2000s,
a nationwide study performed in 40 Spanish
centres demonstrated that CTX-M-9 (27.2%),
SHV-12 (23.9%) and CTX-M-14 (20.5%) were
the most prevalent ESBLs in E. coli strains from
humans [37]. Again, there is no direct evidence to
substantiate the transmission of CTX-M produc-
ers from food-producing animals to humans
through the food chain, since the higher preva-
lence in human isolates cannot be directly corre-
lated with the sporadic isolation observed in the
bacterial population circulating in animals. The
diffusion of these ESBLs might have started to
increase only recently in animals, probably as a
consequence of the wide diffusion in humans.
Interestingly, in a study performed in France
during 2002–2003, using isolates from poultry
and humans, eight S. Virchow-producing CTX-
M-9 strains were identiﬁed on farms in the south-
west of France, and one such isolate caused a case
of gastroenteritis in a 4-year-old child [23]. Until
now, these ESBLs have had a very low prevalence
in France, but their occurrence in S. Virchow
from food-producing animals might be respons-
ible for a rapid increase in this resistance in the
near future. It is of note that three S. Virchow
with enzyme CTX-M-9 have very recently been
isolated in Denmark from quails imported from
France [24], thus suggesting the potential spread
of this ESBL through the food-products trade
among European countries. For example, E. coli
strains producing this ESBL variant were also
recently identiﬁed in rabbits, poultry and pigs in
Spain [26].
In the UK, the most prevalent CTX-M variant
among human isolates, including salmonellae, is
CTX-M-15 (90%)—which is rarely detected in
bacteria from animals in this country,
[20,27]—whereas CTX-M-3 and CTX-M-9 are rare
[38]. A retrospective study of 106 Salmonella
isolates of human origin, collected during 1997–
2003 showed high-level resistance to cephalospo-
rins. Fourteen isolates were CTX-M-positive,
among them, eight S. Virchow strains producing
CTX-M-9 and two Salmonella strains of other
serotypes producing CTX-M-14. Four of the
CTX-M-9-positive strains were associated with
travel to Spain, and one of the CTX-M-14 pro-
ducers was associated with travel to Thailand,
thus indicating very low circulation of CTX-M-14
producers in animals and humans in the UK itself
[20,27]. In November 2004, CTX-M-14-producing
E. coli were isolated from calves on a farm in the
UK. A longitudinal study performed between
December 2004 and July 2005 demonstrated the
rapid diffusion of this ESBL within one farm [28].
120 Clinical Microbiology and Infection, Volume 14, Supplement 1, January 2008
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 117–123
The proportion of positive calf samples rose from
64.6% at the ﬁrst visit to 92.7% at the third visit.
During the latter visit, CTX-M-14-producing
E. coli strains were also isolated from calves,
cattle and ﬂoor samples of a calf barn. The isolates
were genetically unrelated, and the diffusion of
the blaCTX-M-14 gene was related to the spread of a
common, highly promiscuous plasmid among
the intestinal ﬂora of the animals through the
contamination of the farm environment [24].
These ﬁndings indicate a signiﬁcant increase in
the prevalence of these ESBL producers in
cattle in the UK, with probability of diffusion of
genes or strains to the bacterial populations
circulating in humans.
SHV-12
In 2000, a clonal SHV-12-producing Salmonella
strain of an unusual serotype [35:c:1,2] was
detected in human and poultry specimens in
West Africa, suggesting an outbreak associated
with consumption of contaminated food [30]. In
Europe, an SHV-12-producing E. coli strain was
reported in 2001 in Spain, originating from a dog
with recurrent urinary tract infections [2]. Rare
SHV-12-producing E. coli strains were then spo-
radically recovered in faecal samples from
healthy chickens collected during 2000–2001 in
slaughterhouses in Spain [26], and in clinical
samples from pets during 2000–2003 in Italy [15].
SHV-12 ESBL-producing Salmonella strains from
outpatients were reported in the late 1990s in Italy
and Austria, but the association with food con-
sumption was not determined with certainty
[39,40]. More recently, this gene variant has been
described in E. coli and Salmonella isolated from
poultry and pigs in different countries; thus,
it would be of particular interest to monitor its
future global diffusion [11,19,25,26,31].
TEM-52
Production of TEM-type ESBLs has been seen in
non-typhoid Salmonella of human origin, in var-
ious countries. In some European cases the index
strains had probably been introduced by patients
travelling abroad [7]. However, a study per-
formed during 2001–2002 on amoxicillin-resistant
Salmonella isolated from poultry, poultry products
and human patients in The Netherlands revealed
TEM-52 as the most common ESBL throughout
[19]. TEM-52-producing salmonellae of the Block-
ley, Virchow, Typhimurium and Paratyphi B
serotypes were identiﬁed in poultry, and strains
of the Thompson, London, Enteriditis and Block-
ley serotypes in human patients [19]. The differ-
ent Salmonella serotypes strongly contraindicated
a direct association between the human cases and
food consumption [19]. However, the frequent
occurrence of this ESBL in food products is of
concern in the context of future diffusion. Salmo-
nella seems to be the preferred reservoir for this
ESBL (e.g., in France, during 2002–2003, TEM-52
was detected in Salmonella Typhimurium, Salmo-
nella Enteriditis, Salmonella Panama, and Salmo-
nella Blockley human isolates, but only one case
had a suspected link to food consumption) [23]. In
general, very few TEM-52 producers are reported
in animals; three from healthy dogs in Portugal,
three from a single rabbit and poultry in Spain,
and one strain among 732 E. coli isolates from
poultry, beef and pork in Denmark [10–12,35].
Thus, there is no clear link between animals and
humans concerning the spread of the TEM-52
enzyme.
CONCLUSION
ESBL producers are not frequent in animals, and
there is no direct evidence of the transmission of
ESBL-positive zoonotic pathogens to humans
through the food chain. However, recent data
indicate that this picture could rapidly change,
given the increasing reports of several different
ESBL variants worldwide. Some ESBLs seem to
be conﬁned to a speciﬁc geographical region;
whereas others are more widely diffused. The
increased frequency of detection of speciﬁc resis-
tance determinants does not seem to be linked to
the expansion of bacterial clones, but rather, to
plasmid-mediated horizontal gene transmission,
promoting dissemination in speciﬁc areas. In light
of this, it remains necessary to improve our
understanding of the factors that contribute to
the dissemination of resistant microbes among
humans and animals, and to evaluate the role of
the faecal ﬂora in the diffusion of antimicrobial
resistance, as well as on the mechanisms of
linkage and transmissibility of resistance deter-
minants in natural environments. Gut colonisers
of both humans and animals may play an impor-
tant role in the dissemination of resistance. In
animals, the spread of resistance genes could be
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due to promiscuity in animal breeding, and the
genes selected by the use of antimicrobial agents.
It is interesting to note that, despite the use of
different cephalosporins in veterinary medicine,
there is no speciﬁc b-lactamase associated with
animals and that only a few E. coli producers of
the CTX-M-15 variant, which is one of the most
prevalent in humans have been identiﬁed in
animals [13,41]. This observation could suggest
that the selective agents of ESBLs in animals are
not similar to ceftazidime (a good substrate
for CTX-M-15) and that there is no clear link
between animals and humans concerning the
emergence of CTX-M-15. It is important to
emphasise that, often, some ESBL genes are
located within mobile genetic elements, associ-
ated with other resistance genes, conferring resis-
tance to antimicrobials that could be extensively
used among animals and humans (e.g., trimeth-
oprim, sulfamethoxazole, streptomycin) and
which could play an important role in the
co-selection of these ESBL genes. ESBL producers
are expected to increase in the future, in both
animals and humans, and more prudent use of
antimicrobials in general may be necessary, as
well as the implementation of international mea-
sures to control zoonotic pathogens and limit the
global emergence of these resistance traits.
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